Read the source before the claim

Approved, compounded or investigational?

Start with the exact product, route and indication. Approval of one medicine does not approve every substance with a similar name or every proposed use.

FDA says compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing. Compounding can serve a specific medical need; that is different from approval of the finished compounded product.

An investigational trial or a regulatory designation is not permission to market a treatment. Look for the original decision rather than a clinic headline.

How to read a compounding notice

Read the date and the precise kind of action: safety notice, advisory vote, import alert, nomination or a final rule. They are different events.

Keep the named substances and product limits attached to the notice. A bulk-substance nomination is not an FDA approval.

Do not infer safety from the absence of a warning. Ask a licensed clinician to explain the exact product and alternatives.

Questions before HRT or IV care

Ask who will evaluate and prescribe, and check that person’s current license in your state. Ask which exact service and location the clinic confirms.

For testosterone, FDA’s February 2025 labeling change retained the limitation for age-related low testosterone and added or strengthened blood-pressure warnings. Removal of one boxed-warning statement is not absence of risk.

FDA’s February 2026 menopausal hormone labeling announcement covers six products. It does not mean every hormone preparation has the same label or risk.

For IV care, ask how the practice follows infection-control standards and explains the evidence for the proposed use. CDC safety practices address infection prevention, not proof of wellness-infusion benefit.